Morgan Stanley Outlook Therapeutics, Inc. Transaction History

Morgan Stanley

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.22 - $0.66 $79,082 - $237,248	359,467 Added 247.9%	504,471 $196,000
Q3 2023 Nov 15, 2023	SELL	$0.2 - $1.78 $11,239 - $100,034	-56,199 Reduced 27.93%	145,004 $31,000
Q2 2023 Aug 14, 2023	BUY	$1.02 - $1.89 $41,291 - $76,510	40,482 Added 25.19%	201,203 $350,000
Q1 2023 May 15, 2023	BUY	$1.0 - $1.35 $65,569 - $88,518	65,569 Added 68.91%	160,721 $175,000
Q4 2022 Feb 14, 2023	BUY	$0.87 - $1.33 $28,369 - $43,369	32,609 Added 52.14%	95,152 $102,000

Q3 2022 Nov 14, 2022	BUY	$1.02 - $1.26 $12,428 - $15,353	12,185 Added 24.2%	62,543 $75,000
Q2 2022 Oct 27, 2022	SELL	$0.91 - $2.01 $1,971 - $4,355	-2,167 Reduced 4.13%	50,358 $52,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $1,971 - $4,355	-2,167 Reduced 4.13%	50,358 $52,000
Q1 2022 Oct 27, 2022	BUY	$1.22 - $2.03 $2,643 - $4,399	2,167 Added 4.3%	52,525 $94,000
Q1 2022 May 13, 2022	BUY	$1.22 - $2.03 $15,036 - $25,019	12,325 Added 30.66%	52,525 $94,000
Q4 2021 Feb 14, 2022	SELL	$1.27 - $2.23 $247,303 - $434,241	-194,727 Reduced 82.89%	40,200 $55,000
Q3 2021 Nov 15, 2021	BUY	$2.12 - $2.76 $498,045 - $648,398	234,927 New	234,927 $509,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.67B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.